List of Excipients in Branded Drug CONSTULOSE

Generic Drugs Containing CONSTULOSE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	lactulose	45963-439	FRUCTOSE
Actavis Pharma Inc	lactulose	45963-439	GALACTOSE
Actavis Pharma Inc	lactulose	45963-439	LACTOSE
A-S Medication Solutions	lactulose	50090-3436	FRUCTOSE
A-S Medication Solutions	lactulose	50090-3436	GALACTOSE
A-S Medication Solutions	lactulose	50090-3436	LACTOSE

What are the Most Frequently-Used Excipients in CONSTULOSE?

# Of NDCs	Excipient
2	FRUCTOSE
2	GALACTOSE
2	LACTOSE

Constulose Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Constulose is a lactulose oral solution used primarily for constipation and reduction of intestinal ammonia in hepatic encephalopathy. Its commercial opportunity is driven less by active-ingredient exclusivity than by product design, patient adherence, packaging, dispensing efficiency, and channel economics. The strongest opportunities are flavored unit-dose formats, pediatric and geriatric presentation improvements, hospital packaging, and differentiated delivery systems that preserve lactulose’s established clinical profile.

What is Constulose and how is it regulated?

Constulose contains lactulose, a synthetic disaccharide administered as an oral solution. Lactulose is metabolized in the colon into organic acids that lower colonic pH and increase stool water content. In hepatic encephalopathy, the resulting acidification and catharsis reduce intestinal ammonia absorption.

Attribute	Constulose
Active ingredient	Lactulose
Dosage form	Oral solution
Common strength	10 g per 15 mL
Main indications	Constipation; portal-systemic encephalopathy
FDA status	Prescription drug
Administration	Oral, generally measured by volume
Key patient groups	Adults, children, older adults, patients with liver disease
Principal tolerability issues	Bloating, cramping, flatulence, diarrhea
Main formulation challenge	Taste, dose volume, viscosity, and gastrointestinal tolerability

The product is an oral solution rather than a suspension or solid dosage form. That limits the role of conventional excipient innovation. The commercial value lies in optimizing the vehicle, flavor, packaging, and dosing experience while maintaining chemical stability and microbiological quality.

What excipients are used in Constulose?

Constulose is fundamentally a lactulose-in-water formulation. Lactulose products may contain small quantities of related sugars, including lactose, galactose, fructose, and other carbohydrate species resulting from manufacture and equilibrium reactions. These materials are relevant to labeling and patient counseling but should not automatically be treated as intentionally added excipients.

The product’s principal formulation elements are:

Formulation element	Strategic relevance
Purified water	Solvent and primary vehicle
Lactulose	Active ingredient and major contributor to sweetness and osmolality
Process-related sugars	May affect diabetic warnings, impurity controls, and product consistency
Flavor system, if used	Potential adherence differentiator
Preservative system, if used	Microbial-control option, subject to tolerability and labeling review
Packaging components	Important for dose accuracy, leakage control, and stability

Constulose labeling warns that lactulose contains small amounts of galactose and lactose. This is relevant to patients with galactosemia, lactose intolerance, diabetes, and carbohydrate-restricted diets. Product developers should distinguish between the active lactulose load and process-related sugars when evaluating a new formulation or making nutritional claims (U.S. Food and Drug Administration [FDA], n.d.-a).

What excipient strategy is most commercially attractive?

The highest-value strategy is a patient-experience platform rather than a new chemical excipient platform. Lactulose is sweet, viscous, and often associated with gas and bloating. The formulation must improve acceptability without materially changing dose delivery or gastrointestinal effects.

Flavor masking and palatability

Flavor development is the most direct opportunity. Suitable concepts include:

• Citrus or lemon profiles to counter the heavy sweetness.
• Berry flavors for pediatric and caregiver acceptance.
• Neutral flavor systems for patients who mix lactulose with water, juice, or milk.
• Low-aroma formulations for institutional use.
• Two or more flavor variants under the same strength and dosage platform.

Flavor selection must account for lactulose’s sweetness, acidity, viscosity, and potential interaction with the container closure system. A flavor that performs well in a small sensory sample may become unacceptable after accelerated storage or repeated bottle opening.

A differentiated flavor does not generally create meaningful patent protection by itself. Its value is commercial and regulatory: better adherence, improved patient satisfaction, and potential product-line segmentation.

Preservative-free and microbiologically controlled formats

A preservative-free multidose product could appeal to pediatric, geriatric, and medically complex patients. The tradeoff is greater dependence on container design, manufacturing controls, in-use stability, and bottle-opening behavior.

A preservative-containing formulation may provide a simpler multidose strategy, but preservatives can create taste and tolerability concerns. A unit-dose presentation can reduce the need for a conventional preservative system, particularly in hospitals, long-term-care facilities, and specialty pharmacies.

The key development question is whether the product can meet microbial limits and maintain stability through the labeled in-use period. Any change to preservatives, container size, or closure configuration would require CMC assessment and potentially regulatory supplementation.

Viscosity and dose-delivery control

Lactulose solutions are commonly administered in relatively large volumes. Excessive viscosity can impair pouring and oral-syringe withdrawal. Low viscosity can increase spillage and reduce dose control.

Potential improvements include:

• A calibrated oral syringe rather than a household spoon.
• An adapter-compatible bottle.
• A low-drip closure.
• A unit-dose cup with volume markings.
• A ready-to-administer sachet or stick pack.

Adding a thickener could improve coating and pouring behavior, but it may also increase dose variability, alter mouthfeel, and intensify the perception of gastrointestinal fullness. A viscosity modifier is therefore more likely to produce technical risk than meaningful therapeutic differentiation.

What formulations are protected by patents?

Constulose and lactulose have limited apparent exclusivity value because lactulose is an old active ingredient with FDA approval dating to the 1970s. The principal commercial products are generally exposed to generic competition, and the product’s value is not based on a recently issued composition-of-matter patent.

Potentially protectable areas include:

Protection area	Commercial potential	Patent strength
New lactulose chemical entity	Very low	Weak or unavailable for an old active
Standard aqueous solution	Low	Weak
Flavor composition	Moderate	Narrow and easy to design around
Preservative-free system	Moderate	Dependent on technical results
Unit-dose packaging	Moderate	Usually design and execution driven
Oral-syringe dosing system	Moderate	May support device or combination claims
Stability-enhanced formulation	Moderate	Stronger if supported by unexpected data
Modified-release lactulose	High in theory	Technically difficult and commercially uncertain
Microbiome-targeted combination	High in theory	Requires clinical and regulatory investment

The strongest formulation patent would need to claim a specific excipient combination that produces a measurable technical effect, such as improved chemical stability, reduced degradation, superior microbial robustness, or materially improved patient acceptability. A claim limited to “lactulose plus flavor” would likely face validity and design-around pressure.

When does Constulose lose exclusivity?

Constulose has no apparent high-value new-drug exclusivity position comparable to recently approved branded medicines. The relevant competitive issue is generic substitution, not the expiration of a late-stage patent estate.

Exclusivity category	Constulose assessment
New chemical entity exclusivity	Not commercially relevant
Orphan exclusivity	Not applicable to the established product indication
Pediatric exclusivity	No product-specific extension should be assumed
Orange Book patent barrier	No major patent barrier is identified in the standard product profile
Generic competition	Established risk
Formulation differentiation	Main remaining commercial lever

FDA-approved lactulose products can compete through abbreviated new drug applications where applicable. The absence of meaningful active-ingredient exclusivity makes manufacturing cost, distribution, flavor, packaging, and supply reliability more important than patent duration.

What is the Orange Book and FDA regulatory status of Constulose?

Constulose is marketed as a prescription lactulose oral solution. The FDA-approved labeling identifies the indications, dosing, warnings, and carbohydrate-related considerations. The Orange Book is relevant for determining listed patents and therapeutic-equivalence information, but lactulose’s competitive profile is primarily generic and product-based rather than patent-led (FDA, n.d.-b).

A reformulated Constulose product would likely require one of the following regulatory approaches:

• An amended or supplemental application for changes to an existing approved product.
• An ANDA for a generic or therapeutically equivalent product.
• A new drug application or 505(b)(2) pathway for a materially differentiated formulation or delivery system.

A reformulation that changes only flavor, container size, or closure design may be manageable through a CMC supplement or an ANDA amendment, depending on the sponsor’s regulatory position and the nature of the change. A modified-release, combination, or materially different delivery system would require a more substantial regulatory package.

What generic entry risks exist for Constulose?

Generic entry risk is high because:

1. Lactulose is an established active ingredient.
2. The product is a simple oral solution.
3. The manufacturing process is comparatively accessible.
4. The clinical indications are well established.
5. Patient switching generally does not require complex device training.
6. There is no apparent composition-of-matter barrier.

The main generic risks are price compression and pharmacy substitution. A branded product can reduce this exposure through formats that are difficult to replicate commercially, even when they are not strongly protected by patents.

The most defensible differentiation may be operational rather than legal:

• Reliable supply during generic shortages.
• Consistent flavor and viscosity.
• Ready-to-administer hospital packaging.
• Pediatric oral-syringe compatibility.
• Lower-spill packaging for home use.
• Better cold-chain avoidance or high-temperature stability.
• Contracted distribution through liver-disease and long-term-care channels.

How does Constulose compare with competing constipation products?

Product category	Main advantage	Main disadvantage	Excipient opportunity
Lactulose	Also used in hepatic encephalopathy	Sweetness, gas, large dose volume	Flavor, packaging, dose control
PEG 3350	Broad constipation use, low taste burden in some formats	Requires dissolution; not used for the same encephalopathy role	Flavor and rapid-dissolution systems
Sorbitol	Low-cost osmotic option	GI discomfort and taste	Concentration and palatability
Magnesium salts	Familiar and inexpensive	Electrolyte and renal considerations	Safer dosing and palatable liquids
Stimulant laxatives	Lower volume and rapid action	Cramping and chronic-use concerns	Coated or combination formats
Rifaximin	Established role in hepatic encephalopathy prevention	High cost and antibiotic-related economics	Combination and adherence packaging

Constulose retains a clinical niche because it addresses both constipation and hepatic encephalopathy. That dual-use position supports specialty distribution and hospital demand even where general constipation competition is intense.

What licensing and commercial opportunities exist?

No major product-specific licensing transaction is central to Constulose’s commercial profile. The opportunity is more likely to involve co-development, contract manufacturing, or private-label commercialization.

High-potential opportunities

1. Hospital unit-dose lactulose
   Single-use cups or sachets can reduce preparation time, dosing errors, and cross-contamination concerns.

2. Pediatric and geriatric presentation
   Oral-syringe-compatible bottles, calibrated dosing adapters, and palatability-focused flavors can support caregiver adherence.

3. Specialty hepatology packaging
   A liver-disease-focused package could combine dosing instructions, stool-frequency tracking, and refill support without changing the active ingredient.

4. Institutional supply contracts
   Long-term-care facilities and hospitals may value dependable supply, tamper evidence, and low-spill administration more than retail branding.

5. Private-label flavored lactulose
   Pharmacy chains, specialty distributors, and health systems could use differentiated flavors or packaging under private-label arrangements.

6. Stable, preservative-minimized formulation
   A formulation with validated in-use stability could support premium positioning if it reduces waste and administration complexity.

What patent litigation affects Constulose?

There is no prominent patent-litigation profile associated with Constulose comparable to major branded drugs facing Paragraph IV challenges. Litigation risk is more likely to arise from:

• ANDA patent disputes involving a newly patented formulation.
• Trade dress or packaging claims.
• Device claims covering dose measurement.
• Manufacturing-process patents.
• Contract disputes involving private-label or supply arrangements.

A sponsor seeking durable protection should prioritize formulation claims supported by comparative stability or performance data. Packaging patents alone are unlikely to prevent substitution if the underlying lactulose solution remains therapeutically equivalent.

How strong is the Constulose patent estate?

The patent estate is weak as a primary commercial defense and stronger as a platform for incremental product differentiation. The active ingredient is old, the dosage form is simple, and generic substitution is feasible. A new entrant should not base its investment case on blocking generic lactulose.

A commercially credible strategy would combine:

• A narrow formulation patent, where technical data support it.
• Trademark and trade dress protection.
• Device or packaging rights.
• Manufacturing know-how.
• Specialty-channel contracts.
• Reliable supply and differentiated patient support.

Key Takeaways

• Constulose is a lactulose oral solution with limited active-ingredient exclusivity value.
• The principal excipient opportunity is flavor, palatability, preservative strategy, and dose-delivery design.
• Unit-dose, oral-syringe-compatible, pediatric, geriatric, and hospital formats offer the clearest commercial opportunities.
• A sugar-free positioning is difficult because lactulose itself is a carbohydrate and the product may contain related sugars.
• Generic entry risk is high, while patent-based blocking power is limited.
• The most defensible commercial moat is likely to combine packaging, manufacturing reliability, specialty distribution, and a narrow formulation or device patent.
• Constulose’s hepatic encephalopathy use provides a specialty-market opportunity that differentiates it from ordinary laxatives.
• Licensing opportunities are more likely to involve co-development, private label, contract manufacturing, or distribution than a conventional patent license.

FAQs

Can Constulose be reformulated without changing the active ingredient?

Yes. Flavor, container closure, preservative system, viscosity, and dose-delivery components can be changed, but each modification requires product-specific CMC and regulatory evaluation.

Is a flavored lactulose product patentable?

Potentially, but protection would usually be narrow. Patent strength depends on a defined composition and evidence of a non-obvious technical or clinical benefit.

Can Constulose be sold over the counter?

A switch from prescription to over-the-counter status would require FDA review of labeling, consumer self-selection, dosing, and safety. A commercial sponsor should not assume that an established prescription product qualifies automatically for OTC status.

Is Constulose suitable for a pediatric unit-dose product?

Yes, provided the dose presentation, flavor, closure system, microbial controls, and dosing instructions are validated for pediatric use.

What is the best commercial format for a differentiated lactulose product?

A preservative-minimized, flavored, oral-syringe-compatible product in unit-dose or low-spill packaging has the strongest combination of adherence, institutional, and specialty-channel potential.

References

1. U.S. Food and Drug Administration. (n.d.-a). Constulose (lactulose solution, USP) prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. United States Pharmacopeia. (2024). Lactulose oral solution monograph. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (1997). SUPAC-SS: Nonsterile semisolid dosage forms scale-up and postapproval changes. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2016). ANDAs for certain highly purified synthetic peptides and related products: Guidance for industry. Center for Drug Evaluation and Research.